A systematic review of duloxetine and venlafaxine in major depression, including unpublished data

  title={A systematic review of duloxetine and venlafaxine in major depression, including unpublished data},
  author={Y-B Schueler and Markus Koesters and Beate Wieseler and Ulrich Grouven and Mandy Kromp and Michaela F. Kerekes and J Kreis and Thomas Kaiser and Thomas Becker and Stefan Weinmann},
  journal={Acta Psychiatrica Scandinavica},
Schueler Y‐B, Koesters M, Wieseler B, Grouven U, Kromp M, Kerekes MF, Kreis J, Kaiser T, Becker T, Weinmann S. A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. 

The safety of serotonin–noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review

A comprehensive review of the existing literature on the safety of serotonin–noradrenaline reuptake inhibitors (SNRIs) in pregnancy and lactation is provided.

Systematic evaluation of the ‘efficacy‐effectiveness gap’ in the treatment of depression with venlafaxine and duloxetine

Evidence of larger drug effects in highly standardized studies (efficacy) compared to clinical routine (effectiveness) is discussed as efficacy‐effectiveness gap. This study aimed to quantify effect

Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies

This meta-analysis includes all published, randomized, double-blind, head-to-head trials, which compared venlafaxine and an SSRI in the treatment of MDD in adults, and shows that venl Lafaxine was superior to SSRIs in achieving remission and response.

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review

The efficacy in the acute treatment of Esc vs Dul varied, however, the tolerability of Esc was superior to Dul in acute MDD treatment, and selection between the 2 antidepressants may depend on the tolerable of MDD patients.

A meta-analysis of the efficacy of venlafaxine extended release 75–225 mg/day for the treatment of major depressive disorder

Venlafaxine ER 75–225 mg/day effectively reduced symptoms of depression in patients with MDD overall and in patientswith either lower (≤23) or higher (>23) HAM-D17 total score at baseline.

Duloxetine in the acute and continuation treatment of major depressive disorder

duloxetine is of interest in the treatment of certain conditions commonly seen in conjunction with major depression, particularly anxiety and pain, both of which may respond more favorably to agents that act on both serotonin and noradrenaline neurotransmitter systems.

Pharmacological management of unipolar depression

To provide clinically relevant recommendations for the use of pharmacological treatments in depression derived from a literature review.

Systematic Review and Meta-Analysis of Vortioxetine for the Treatment of Major Depressive Disorder in Adults

Vortioxetine is more advantageous over placebo in treating MDD among adults, but no significant difference compared to SNRIs and SSRIs in general.



A double‐blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia

The antidepressant efficacy and short-term safety of venlafaxine and fluoxetine were compared in 68 patients hospitalized with major depression and melancholia and overall tolerance was similar for the two treatments.

Is there a place for ▼duloxetine?

  • Medicine
    Drug and therapeutics bulletin
  • 2007
Whether duloxetine has a role in the treatment of patients with major depression, diabetic peripheral neuropathic pain, stress urinary incontinence or any of these conditions is considered.

Efficacy of venlafaxine in depressive illness in general practice

Venlafaxine was significantly superior to both imipramine and placebo for the SARS total score and the items 'socialeisure’and‘extended family’ and a similar proportion of patients discontinued treatment in each group, but fewer patients on venlafxine discontinued treatment because of an unsatisfactory response.

Venlafaxine versus nortriptyline in the treatment of elderly depressed inpatients: a randomised, double‐blind, controlled trial

The majority of the trials in the elderly are outpatient trials which excluded psychotic patients and patients with common comorbid physical disorders. Consequently information is lacking about the

Duloxetine for the treatment of major depressive disorder.

Duloxetine was demonstrated to be safe and effective in the treatment of MDD and the starting dose with the best balance of efficacy and tolerability is 60 mg QD.

Randomized, Double-Blind Comparison of Venlafaxine and Sertraline in Outpatients With Major Depressive Disorder

Among patients who increased their dose, approximately twice as many experienced a remission with venlafaxine, which is a more clinically relevant endpoint than response and represents the proportion of patients who have recovered or are well.

A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.

Results of this study indicate that, when titrated rapidly to their maximum recommended doses, escitalopram is at least as effective as venlafaxine XR and significantly better tolerated and do not support the hypothesis that nonselective SRIs have greater efficacy than selective SRIs.

Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms.

SERTraline and venlafaxine XR demonstrated comparable effects on QOL and efficacy in treatment of major depression, although sertraline may be associated with a lower symptom burden during treatment discontinuation and a reduced risk of blood pressure increase.

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

Duloxetine is efficacious for the treatment of major depressive disorder and is well tolerated and safe, and insomnia and asthenia were the only adverse events reported statistically significantly (p < .05) more frequently by duloxettine-treated patients compared with placebo- treated patients.

Efficacy of Duloxetine and Selective Serotonin Reuptake Inhibitors: Comparisons as Assessed by Remission Rates in Patients With Major Depressive Disorder

Whereas duloxetine and the 2 SSRIs were comparably efficacious overall, therapy with the serotonin and norepinephrine reuptake inhibitor resulted in a significantly higher remission rate among patients with moderate-to-severe depression.